William Plovanic Resigns as President and Chief Executive Officer and Will Continue to Serve Solely as Director
To assist the Company in the transition,
Due to impact of COVID-19 and the “stay at home” directives issued by the Governor of
Cautionary Statement Regarding Forward Looking Statements
This press release contains forward-looking statements that are not purely historical regarding Obalon’s or its management’s intentions, beliefs, expectations and strategies for the future, including those related to new products and their potential benefits. All forward-looking statements and reasons why results might differ included in this press release are made as of the date of this release, based on information currently available to Obalon, deal with future events, are subject to various risks and uncertainties, and actual results could differ materially from those anticipated in those forward looking statements. The risks and uncertainties that may cause actual results to differ materially from Obalon’s current expectations are more fully described in Obalon’s annual report on Form 10-K for the period ended
President and Chief Executive Officer
Office: +1 760 607 5103
Source: Obalon Therapeutics, Inc.